Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (7572)	12/20/2002 3:06:58 PM
From: keokalani'nui	Read Replies (1) \| Respond to of 52153

But Ocinaplon and bicifadine (if I recall correctly) have only Waxman-Hatch (5 year) patent protection, which substantially reduces their value. Biomaven, I recognize this is off the top of your head. But with the Elan controlled-release technology, wouldn't these be novel and, at minimum, subject to patent for the life of Elan's patents?

To: Biomaven who wrote (7572)	12/20/2002 3:14:09 PM
From: NeuroInvestment	Read Replies (2) \| Respond to of 52153

Peter: 1) Ocinaplon is being developed and tested in a time-release reformulation, which they believe improves pharmacokinetics and gives them patent protection beyond 2007--and no generics maker is going to run Phase II and III on original ocinaplon. They are talking--though this is far from established--about filing for what they claim is their unique IP for mechanisms of non-sedating anxiolysis (the second company who told me today about plans to attempt broad mechanism/target based use patents akin to what Cortex did with Ampakines.) May not work in Europe, might work in the US. 2) They have filed for patent on the crystalline structure of bicifadine--and say that any alternate stucture immediately degrades to their's, thus infringing on their patent-pending. (similar to structure strategy successfully used by NBIX on Indiplon) I have no idea about the angina drug, it doesnt will enter into my assessment. Whether they will succeed or not I do not know, but they have an active strategy for extending proprietary control. Harry NeuroInvestment